Previous 10 | Next 10 |
Mapi Pharma Ltd., a partner of generic drugmaker Viatris Inc. ( NASDAQ: VTRS ), announced Wednesday that its Phase 3 clinical trial for GA Depot, a long-acting version of multiple sclerosis therapy Copaxone, reached the primary endpoint. The trial, designed to evaluate the o...
NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot injectable products, announced today positive top-line results from the GA Depot (a long ac...
Summary There is one notable trade that is not a buy this month as I decided to shuttle Warner Bros. Discovery, Inc. Today, it seems that every company is engaged in accounting trickery fooling shareholders with crap spin-offs that only disguise real dividend cuts. I continue ...
Summary A high level of restructuring is occurring with the Healthcare industry’s largest constituents. Most restructuring is taking the form of splits or spin-offs, but not all incidences look beneficial. This article will summarize coming transactions and provide comm...
Viatris Inc. (VTRS) BofA Global Research Global Healthcare Conference September 15, 2022 11:45 AM ET Company Participants Michael Goettler – Chief Executive Officer Rajiv Malik – President Sanjeev Narula – Chief Financial Officer Confer...
Pharmaceutical businesses spend billions of dollars developing medicines that they then protect with a fortress of intellectual property (IP) safeguards to make sure that competitors can't benefit from their work. But for companies with a bit of patience, it pays to wait out the years o...
Summary With all the recent market volatility, there is no shortage of stocks that are looking seemingly cheaper when compared to the closing months of 2021. First up, I’m thinking about adding to the recent spin-off Viatris Inc. Finally, I am looking at Verizon Communi...
Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference PR Newswire PITTSBURGH , Sept. 6, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the B...
Summary Viatris's total revenue was $4,116.8 million in Q2 2022, down 10.1% year-on-year. Sales of the company's branded medicines have been declining since the formation of Viatris in 2020. The company has a dividend yield of 5.08%, but dividend payouts are at risk from 2026....
Summary Davis Selected Advisers' 13F portfolio value decreased from $19.79B to $15.59B this quarter. They increased Teck Resources and Owens Corning while reducing Alibaba Group Holding and American Express. The top three positions are Wells Fargo, Berkshire Hathaway, and Capi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...